Apimeds Pharmaceuticals US, Inc
APUS · NYSE
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | – | $18,250 | $25,457 | $25,359 |
| - Cash | $6,987 | $8,735 | $250 | $3 |
| + Debt | $0 | $500 | $874 | $597 |
| Enterprise Value | – | $10,014 | $26,081 | $25,953 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | -$1 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$1,773 | -$2,639 | -$364 | -$276 |
| % Margin | – | – | – | – |
| Net Income | -$1,781 | -$2,662 | -$402 | -$312 |
| % Margin | – | – | – | – |
| EPS Diluted | -0.14 | -0.26 | -0.035 | -0.025 |
| % Growth | 46.2% | -647.1% | -41.5% | – |
| Operating Cash Flow | -$1,726 | -$3,361 | -$20 | -$100 |
| Capital Expenditures | -$23 | -$13 | $0 | $0 |
| Free Cash Flow | -$1,749 | -$3,374 | -$20 | -$100 |